Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 2570Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2057Leukemia, Lymphocytic, Chronic, B-Cell 1771Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1597Leukemia 1172Hodgkin Disease 1128Lymphoma, Mantle-Cell 1110Burkitt Lymphoma 887Leukemia, Myeloid, Acute 885Lymphoma, B-Cell, Marginal Zone 788Recurrence 779Multiple Myeloma 744Lymphoma, B-Cell 704Myelodysplastic Syndromes 615Neoplasms 494Lymphoma, T-Cell, Cutaneous 479Waldenstrom Macroglobulinemia 470Lymphoma, Large-Cell, Immunoblastic 456Mycosis Fungoides 383Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Lymphoma, Large-Cell, Anaplastic 362Sezary Syndrome 321Lymphoma, T-Cell, Peripheral 321Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307Hematologic Neoplasms 299Myeloproliferative Disorders 288Neoplasms, Plasma Cell 270Blast Crisis 261

Interventions

arginine butyrate 1Valganciclovir 1Ganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × EBV Lymphomas × Lymphoid × Clear all
NCT03988582 2020-06-11

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Lymphoid

EBV Lymphomas

NCT00917826 2011-08-01

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

EBV Lymphomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡